XORTX Welcomes New Member to the Board of Directors
08 4월 2024 - 8:30PM
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ:
XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a
late-stage clinical pharmaceutical company focused on developing
innovative therapies to treat progressive kidney disease, welcomes
Abigail Jenkins, a biotech industry veteran with deep experience
with the commercialization of therapies for renal and
cardiovascular disease, to its Board of Directors.
Abigail “Abbey” L. Jenkins, M.S., is the current
President and CEO of Gamida Cell (NASDAQ: GMDA) and a member of its
Board of Directors. Ms. Jenkins brings over 20 years of leadership
experience in the biopharmaceutical industry delivering
life-enhancing therapies from research to commercialization for
patients in need. Prior to joining Gamida Cell, she was the Chief
Commercial and Business Officer at Lyndra Therapeutics, where she
established and led global commercial, business development,
corporate strategy and portfolio management across multiple
therapeutic areas. Prior to Lyndra, she held the positon of Senior
Vice President and Business Unit Head of Vaccines at Emergent
BioSolutions, where she oversaw Lyndra’s largest therapeutic
division from discovery through commercialization. Ms. Jenkins also
served as Chief Commercial Officer and U.S. Business Head at
Aquinox Pharmaceuticals. Additionally, she has held senior
commercial and business development positions at Relypsa, Actavis,
Pfizer and Medimmune/AZ.
Ms. Jenkins holds a Master of Science in
biotechnology and biotech business enterprise from Johns Hopkins
University, a Bachelor of Arts in psychology and biology from
Indiana University, and a certificate of achievement in General
Management as a Kellogg Executive Scholar. She was recognized in
2022 as one of the PharmaVoice 100, one of the industry’s 100 Most
Inspiring Leaders, Disrupter category, for change agents who define
excellence in leadership in biopharma.
Anthony Giovinazzo, XORTX’s Chairman of the
Board commented, “We are delighted to welcome Abbey to the Board of
Directors. Abbey is a highly skilled and experienced leader who
will significantly contribute to the Board of Directors carrying
out its mandate. Her experience with innovative drug delivery
systems and the launches of novel therapeutics will be extremely
valuable to the Company as it navigates from a Phase 3 clinical
company to being prepared for commercialization of its drug
candidates.”
In connection with the appointment of Abigail
Jenkins, XORTX has granted, in accordance with the Company’s stock
option plan, 8,000 options to purchase common shares of the Company
at an exercise price of $5.00 for a period of five years.
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with two
clinically advanced products in development: 1) our lead, XRx-008
program for ADPKD; and 2) our secondary program in XRx-101 for
acute kidney and other acute organ injury associated with
Coronavirus / COVID-19 infection. In addition, XRx-225 is a
pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX
is working to advance its clinical development stage products that
target aberrant purine metabolism and xanthine oxidase to decrease
or inhibit production of uric acid. At XORTX, we are dedicated to
developing medications to improve the quality of life and future
health of patients. Additional information on XORTX is available at
www.xortx.com.
For more
information, please contact: |
|
|
|
Allen Davidoff, CEO |
Nick Rigopulos, Director of Communications |
adavidoff@xortx.com or +1 403 455 7727 |
nick@alpineequityadv.com or +1 617 901 0785 |
|
|
Kim Golodetz, LHA Investor Relations |
|
kgolodetz@lhai.com or 1 212 838 3777 |
|
|
|
Neither the TSX Venture Exchange nor Nasdaq has
approved or disapproved the contents of this news release. No stock
exchange, securities commission or other regulatory authority has
approved or disapproved the information contained herein.
Forward Looking Statements
This press release
contains express or implied forward-looking statements pursuant to
applicable securities laws. These forward-looking statements and
their implications are based on the current expectations of the
management of XORTX only, and are subject to a number of factors
and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
Except as otherwise required by applicable law and stock exchange
rules, XORTX undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. More detailed information about the risks and
uncertainties affecting XORTX is contained under the heading “Risk
Factors” in XORTX’s Annual Report on Form 20-F filed with the SEC,
which is available on the SEC's website, www.sec.gov (including any
documents forming a part thereof or incorporated by reference
therein), as well as in our reports, public disclosure documents
and other filings with the securities commissions and other
regulatory bodies in Canada, which are available on
www.sedarplus.ca.
Xortx Therapeutics (TSXV:XRTX)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Xortx Therapeutics (TSXV:XRTX)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024